In other genetic disorders with increased ECM deposition, preclinical studies and phase I–III trials have aimed to downregulate TGF-β1 using antibodies or soluble TGF-β1 receptors as scavengers, or by blocking the activation of latent TGF-β1. Here, TGFB1 is linked to hereditary disease.